|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
1997-2-26
|
|
pubmed:abstractText |
CPT-11 (irinotecan), a camptothecin-derived anticancer agent with DNA topoisomerase 1 inhibitory activity, has demonstrated a broad spectrum of in vitro and in vivo activity in solid tumour models including multidrug-resistant tumours. This review details the rationale for the dosage schedule of CPT-11 selected for phase II studies, based on the results of 3 European phase I dose-escalating trials in patients with solid tumours.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
7
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
837-42
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8922198-Adolescent,
pubmed-meshheading:8922198-Adult,
pubmed-meshheading:8922198-Aged,
pubmed-meshheading:8922198-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:8922198-Camptothecin,
pubmed-meshheading:8922198-Disease-Free Survival,
pubmed-meshheading:8922198-Dose-Response Relationship, Drug,
pubmed-meshheading:8922198-Drug Administration Schedule,
pubmed-meshheading:8922198-Europe,
pubmed-meshheading:8922198-Female,
pubmed-meshheading:8922198-Humans,
pubmed-meshheading:8922198-Infusions, Intravenous,
pubmed-meshheading:8922198-Male,
pubmed-meshheading:8922198-Middle Aged,
pubmed-meshheading:8922198-Neoplasms,
pubmed-meshheading:8922198-Survival Rate,
pubmed-meshheading:8922198-Treatment Outcome
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies.
|
|
pubmed:affiliation |
Institut Gustave-Roussy, Villejuif, France.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
